Distinguishing between benign and malignant thyroid nodules (TNs) is challenging due to their overlapping imaging features. The rapid advancement of artificial intelligence (AI) in medical image ...
Durable volume reduction was demonstrated with an average volume reduction of 74% of treated benign thyroid nodules at 15-22 months post-treatment. HAYWARD, Calif., March 09, 2026--(BUSINESS ...
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) ...
Durable volume reduction was demonstrated with an average volume reduction of 74% of treated benign thyroid nodules at 15-22 months post-treatment. Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of ...
The CellFX nsPFA percutaneous electrode system. [Image courtesy of Pulse Biosciences] Pulse Biosciences (Nasdaq:PLSE) today announced clinical findings demonstrating the durability of its nPulse ...
Origin in C cells renders disease calcitonin/CEA-secreting and non–iodine-avid, eliminating therapeutic utility of radioactive iodine and emphasizing early, definitive management. Clinical phenotypes ...
Abstract: This paper proposes an ensemble learning based method for classification of thyroid cancer nodules. Thyroid cancer is $10^{\text {th }}$ most common type of cancer found worldwide. According ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results